Adverum Biotechnologies Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADVM Nasdaq 8731 https://adverum.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adverum Biotechnologies Inc

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 18th, 2023 9:05 pm
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results - Nov 10th, 2022 9:05 pm
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022) - Nov 4th, 2022 4:08 pm
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting - Oct 27th, 2022 8:05 pm
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD - Sep 30th, 2022 8:45 pm
Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference - Sep 27th, 2022 8:05 pm
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit - Sep 23rd, 2022 8:05 pm
Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation - Sep 23rd, 2022 3:06 pm
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022 - Sep 23rd, 2022 12:00 pm
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study - Sep 15th, 2022 9:19 pm
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration - Sep 14th, 2022 12:00 pm
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Sep 8th, 2022 8:05 pm
Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase - Aug 26th, 2022 8:05 pm
Adverum Biotechnologies Reports Second Quarter 2022 Financial Results - Aug 11th, 2022 8:05 pm
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference - Aug 10th, 2022 8:05 pm
Quite a few insiders invested in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) last year which is positive news for shareholders - Jul 25th, 2022 11:16 am
Adverum Posts New Data From Wet AMD Gene Therapy Trial - Jul 15th, 2022 1:52 pm
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD - Jul 15th, 2022 12:32 pm
Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022 - Jul 8th, 2022 12:00 pm
Adverum (ADVM) Completes IND Amendment for Gene Therapy Study - Jul 7th, 2022 3:22 pm